Search - tctmd.com

Displaying 61 - 70 of 70

Sort: Relevancy | Date

Presentation TCT 2015

Cangrelor II: Perspectives on in Whom to Actually Use It

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

Cangrelor I: Data Essentials From the Champion Trials

Presenter: Deepak L. Bhatt, Robert A. Harrington, Harvey D. White

October 15, 2015

Presentation TCT 2015

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Presenter: Gary M. Ansel, Michael R. Jaff, Ori Ben-Yehuda

October 11, 2015

News Conference News TCT 2015

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

October 11, 2015

News Conference News TCT 2014

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Todd Neale

September 13, 2014

News Conference News TCT 2013

Studies Find Differing Benefits of Platelet, Genotype Testing

October 31, 2013

News Conference News TCT 2013

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

October 30, 2013

News Conference News TCT 2012

Presentations Examine Multiple Facets of Antiplatelet Agents

October 24, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

Presenter: Dirk Sibbing

October 22, 2012

Presentation TCT 2012

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Presenter: Laurent Bonello

October 22, 2012

Advertisement

Cangrelor II: Perspectives on in Whom to Actually Use It

Cangrelor I: Data Essentials From the Champion Trials

PAR-1 Antagonists and P2Y12 Inhibitors: What Are the Data and the Place of These Medications in the PAD Population (for Secondary Cardiovascular Prevention and PAD Itself)?

Experts Debate Optimal Pharmacologic Approach for STEMI Patients

Skeptic’s Corner: Experts Debate Aspirin Use in Patients with AF Receiving DES

Studies Find Differing Benefits of Platelet, Genotype Testing

EUROMAX: Prehospital Bivalirudin Reduces Bleeding in STEMI

Presentations Examine Multiple Facets of Antiplatelet Agents

P2Y12 Inhibitors: Specific Agents for Specific Patient Cohorts? (STEMI, Diabetes, CKD, Prior Stroke, Etc.)

P2Y12 Inhibitors: Could Platelet Reactivity to Balance Between Bleeding and Ischemic Events

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content